drugset / Trial / NCT01440933

Efficacy of Sugammadex in Magnesium Pretreated Patients

NCT01440933

Phase 2 Completed 32 enrolled University Hospital, Geneva
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Sugammadex is a new reversal agent for neuromuscular blockers (curare). It encapsulates the curare molecule and terminates immediately its action. The recommended dose is 2 mg/kg for a slight neuromuscular block and 4 mg/kg for a profound neuromuscular block. Magnesium sulphate is frequently used in perioperative medicine and it is known to reinforce the neuromuscular block induced for instance by rocuronium. The researchers want to investigate, whether higher doses of sugammadex must be given to antagonize the neuromuscular block induced by rocuronium in patients who received magnesium sulphate.

Timeline

Start
2011-09
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Magnesium Sulfate Other / unclassified 60 mg/kg Intravenous

Indications